方法：选取来我院就诊并通过病史、临床症状及眼底血管照影(FFA/ICGA)和光学相干断层扫描(OCT)等辅助检查确诊的渗出型年龄相关性黄斑变性的患者160例(160眼)，随机分为联合组和对照组，联合组给予单次行玻璃体腔注射Ranibizumab，7d后行TTT治疗，对照组仅行TTT治疗，随访1a，分别于治疗后1wk； 1，6mo； 1a，观察患者的最佳矫正视力、散瞳后眼底的变化及眼底血管照影(FFA/ICGA)及OCT的检查。

结果：观察期末，联合组最佳矫正视力提高34例(42.50%)，对照组最佳矫正视力提高16例(20.00%)，差异具有统计学意义(P<0.05)。治疗后1wk； 1，6mo； 1a联合组和对照组的荧光渗透有效率分别为(88.75%，62.50%)；(91.25%，65.00%)；(86.25%，61.25%)；(78.75%，51.25%)。治疗后1wk； 1，6mo； 1a联合组和对照组黄斑中心厚度分别为：(347.43±36.96)μm和(423.58±29.03)μm；(287.78±34.16)μm和(387.14±32.98)μm；(301.75±37.21)μm和(415.40±31.38)μm；(326.17±27.39)μm和(436.44±35.49)μm，两组相比，差异具有统计学意义(P<0.05)。

结论：玻璃体腔注射Ranibizumab联合经瞳孔温热疗法治疗渗出型年龄相关性黄斑变性，能够使患者的视力得到改善，病灶渗漏停止或减轻，促进黄斑区出血、水肿及渗出的吸收，安全、疗效可靠，是一种有效的临床治疗方法。

METHODS: Totally 160 wet age-related macular degeneration patients(160 eyes )were selected, which have been diagnosed through history, clinical symptoms and fundus angiography(FFA/ICGA)as well as optical coherence tomography(OCT)and other auxiliary examinations in our hospital. All these patients were randomly divided into the combined group and the control group. Combined group was given a single intravitreal injection Ranibizumab and applied the TTT treatment after seven days, while the control group only received the TTT treatment and was being monitored for 1y. The patients' best corrected visual acuity, fundus angiography(FFA/ICGA)and OCT examination were observed after 1wk, 1mo, 6mo and 1y of the treatment, respectively.

RESULTS: By the end of the observation period, there were 34 cases(42.50%)out of the combined group whose the best corrected visual acuity have improved, while 16 cases from the control group(20.00%)whose best corrected visual acuity have improved. The difference between the two groups showed statistically significance(P<0.05). More specifically, the fluorescent penetrant rates are(88.75%, 62.50%),(91.25%, 65.00%),(86.25%, 61.25%),(78.75%, 51.25%), respectively, in both groups after 1wk, 1mo, 6mo and 1y treatment, and also the corresponding central macular thickness(CMT)were(347.43±36.96)μm and(423.58±29.03)μm,(287.78±34.16)μm and(387.14±32.98)μm,(301.75±37.21)μm and(415.40±31.38)μm,(326.17±27.39)μm and(436.44±35.49)μm. In a nutshell, the difference between the two groups were statistically significant(P<0.05).

CONCLUSION: Intravitreal injection of Ranibizumab with TTT treatment applied among patients with wet age-related macular degeneration(AMD)could improve patients' vision, stop or reduce the leakage of the lesion, as well as promote the absorption of macular hemorrhage, edema and exudation, which could be considered as a safe, reliable and effective clinical treatment.